Ten months after spinning off from BD, Embecta CEO Dev Kurdikar lays out what the future holds for the diabetes technology company.
When Embecta became a standalone company in April 2022, CFO Jake Elguicze said he felt it was “uniquely positioned.”
As a pure-play diabetes technology developer, its beginning phase hardly mirrors a normal startup. The former diabetes arm of BD brought with it nearly a century of experience in the space.
Elguicze said Embecta had scale at about $1.2 billion in annual revenue. It also kicked off with a strong geographic reach and no ties to any one product.
Still, CEO Devdatt “Dev” Kurdikar last week told Drug Delivery Business News that the past 10 months still involved a lot of work around the spinoff. But, the future looks bright for Embecta, he says.
“We’ve taken a business that was part of a much larger business for close to 100 years,” Kurdikar explained. “Now, we’re doing the work of separating it. There is a lot of work in standing up your own independent company. So, our team has been hard at work on that.
“There have been just a number of global operating challenges. So in addition to all the work related to the spin, my team has been navigating through all those challenges as well.”
Get the full story at our sister site, Drug Delivery Business News.